A recombinant adenovirus expressing ovine interferon tau prevents influenza virus-induced lethality in mice

Journal of Virology

Volumn 90, Issue 7, 2016, Pages 3783-3788

  Martin V ^a   Pascual, E ^a   Avia, M ^a   Rangel, G ^a   De Molina, A ^b   Alejo, A ^a   Sevilla, N ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERFERON; STAT1 PROTEIN; TAU INTERFERON; VIRUS RNA; INTERFERON; PLACENTA PROTEIN; RECOMBINANT PROTEIN; TROPHOBLAST PROTEIN 1;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA VIRUS; LD50; LETHALITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHEEP; SINGLE DRUG DOSE; VERO CELL LINE; VESICULOVIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; INTERFERON TYPE I; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PREGNANCY PROTEINS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84960968269     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03258-15     Document Type: Article

References (32)

1. Sen GC. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-281. http://dx.doi.org/10.1146/annurev.micro.55.1.255.
2. Honda K, Takaoka A, Taniguchi T. 2006. Type I inteferon [sic] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360. http://dx.doi.org/10.1016/j.immuni.2006.08.009.
3. Brassard DL, Grace MJ, Bordens RW. 2002. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71:565-581.
4. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. 2013. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 208:310-318. http://dx.doi.org/10.1093/infdis/jis921.
5. Müller U, SteinhoffU, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921. http://dx.doi.org/10.1126/science.8009221.
6. Subramaniam PS, Khan SA, Pontzer CH, Johnson HM. 1995. Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Proc Natl Acad Sci U S A 92: 12270-12274. http://dx.doi.org/10.1073/pnas.92.26.12270.
7. Pontzer CH, Yamamoto JK, Bazer FW, Ott TL, Johnson HM. 1997. Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J Immunol 158:4351-4357.
8. Kohara J, Yokomizo Y. 2007. In vitro and in vivo effects of recombinant bovine interferon-tau on bovine leukemia virus. J Vet Med Sci 69:15-19. http://dx.doi.org/10.1292/jvms.69.15.
9. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP. 2013. mAbs and Ad-vectored IFN-α therapy rescue Ebolainfected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 5:207ra143. http://dx.doi.org/10.1126/scitranslmed.3006605.
10. Qiu X, Wong G, Fernando L, Ennis J, Turner JD, Alimonti JB, Yao X, Kobinger GP. 2013. Monoclonal antibodies combined with adenovirusvectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J Virol 87:7754-7757. http://dx.doi.org/10.1128/JVI.00173-13.
11. Zhang L, Wang H, Zhang Y-Q. 2015. Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis. J Zhejiang Univ Sci B 16:1-9. http://dx.doi.org/10.1631/jzus. B1400365.
12. Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, Bailey KW, Vest ZG, Madsen JR, Li JK-K, Barnard DL. 2011. Singledose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res 89:75-82. http://dx.doi.org/10.1016/j.antiviral.2010.11.007.
13. Bazer FW, Spencer TE, Ott TL. 1996. Placental interferons. Am J Reprod Immunol 35:297-308. http://dx.doi.org/10.1111/j.1600-0897.1996.tb00485.x.
14. Takahashi H, Tsunazaki M, Hamano T, Takahashi M, Okuda K, Inumaru S, Okano A, Geshi M, Hirako M. 2014. Biological activity of recombinant bovine interferon τ produced by a silkworm-baculovirus gene expression system. J Vet Med Sci 76:447-451. http://dx.doi.org/10.1292/jvms.12-0403.
15. Winkelman GL, Roberts RM, James Peterson A, Alexenko AP, Ealy AD. 1999. Identification of the expressed forms of ovine interferon-tau in the periimplantation conceptus: sequence relationships and comparative biological activities. Biol Reprod 61:1592-1600. http://dx.doi.org/10.1095/biolreprod61.6.1592.
16. Klemann SW, Imakawa K, Roberts RM. 1990. Sequence variability among ovine trophoblast interferon cDNA. Nucleic Acids Res 18:6724. http://dx.doi.org/10.1093/nar/18.22.6724.
17. Mujtaba MG, Soos JM, Johnson HM. 1997. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J Neuroimmunol 75:35-42. http://dx.doi.org/10.1016/S0165-5728(96)00231-7.
18. Chon TW, Bixler S. 2010. Interferon-tau: current applications and potential in antiviral therapy. J Interferon Cytokine Res 30:477-485. http://dx.doi.org/10.1089/jir.2009.0089.
19. Martal JL, Chêne NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, Charlier MA, Charpigny SY. 1998. IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structurefunction relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 80:755-777.
20. Johnson JA, Hochkeppel HK, Gangemi JD. 1999. IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression. J Interferon Cytokine Res 19:1107-1116. http://dx.doi.org/10.1089/107999099313046.
21. Fujii Y, Murase Y, Otake K, Yokota Y, Omoto S, Hayashi H, Okada H, Okada N, Kawai M, Okuyama H, Imakawa K. 2004. A potential live vector, foamy virus, directed intra-cellular expression of ovine interferontau exhibited the resistance to HIV infection. J Vet Med Sci 66:115-121. http://dx.doi.org/10.1292/jvms.66.115.
22. Rojas JM, Moreno H, García A, Ramírez JC, Sevilla N, Martín V. 2014. Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV. Vaccine 32:393-400. http://dx.doi.org/10.1016/j.vaccine.2013.11.033.
23. Tatsis N, Ertl HCJ. 2004. Adenoviruses as vaccine vectors. Mol Ther 10:616-629. http://dx.doi.org/10.1016/j.ymthe.2004.07.013.
24. Symons JA, Alcamí A, Smith GL. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560. http://dx.doi.org/10.1016/0092-8674(95)90076-4.
25. Horisberger MA, Staeheli P, Haller O. 1983. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad SciUSA80:1910-1914. http://dx.doi.org/10.1073/pnas.80.7.1910.
26. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martínez-Sobrido L, Solórzano A, García-Sastre A, Haller O, Kochs G. 2007. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A 104:6806-6811. http://dx.doi.org/10.1073/pnas.0701849104.
27. Winter G, Fields S, Brownlee GG. 1981. Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype. Nature 292: 72-75. http://dx.doi.org/10.1038/292072a0.
28. Haller O, Arnheiter H, Gresser I, Lindenmann J. 1981. Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. J Exp Med 154:199-203.
29. Sanders CJ, Johnson B, Frevert CW, Thomas PG. 2013. Intranasal influenza infection of mice and methods to evaluate progression and outcome. Methods Mol Biol 1031:177-188. http://dx.doi.org/10.1007/978-1-62703-481-4_20.
30. Der SD, Yang YL, Weissmann C, Williams BR. 1997. A double-stranded RNA-activated protein kinase-dependent pathway mediating stressinduced apoptosis. Proc Natl Acad Sci U S A 94:3279-3283. http://dx.doi.org/10.1073/pnas.94.7.3279.
31. Tang Y, Zhong G, Zhu L, Liu X, Shan Y, Feng H, Bu Z, Chen H, Wang C. 2010. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J Immunol 184:5777-5790. http://dx.doi.org/10.4049/jimmunol.0903588.
32. Zhao C, Hsiang T-Y, Kuo R-L, Krug RM. 2010. ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. Proc Natl Acad Sci U S A 107:2253-2258. http://dx.doi.org/10.1073/pnas.0909144107.